It was already known that almost 60% of all marketed anti-tumor agents could be recognized by P-gp and then were pumped out of the cells back to the blood flow, resulting in reduced therapeutic efficacy and poor brain accumulation of drugs (van Tellingen et al., 2015). The gene discussed is PGP; the disease is neoplasm.